SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Beyond Meat Inc

Beyond Meat is seeing massive trading volume and heightened volatility as traders weigh the potential for a short squeeze against concerns of a broader market downturn. While some retail investors are treating recent price action as a reloading opportunity, others are skeptical of the stock's long-term sustainability and are debating whether the current momentum represents a genuine breakout or an eventual fade.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group continues to see extreme volatility and intense debate among traders as it remains a focal point for a massive, multi-week short squeeze. The community is heavily split, with many retail participants warning of an inevitable and sharp correction while others aggressively push for further upside, fueled by concerns over a constrained float and the high cost of borrowing shares.

Faraday Future Intelligent Electric, Inc. is an emerging growth company, which manufactures electric vehicles. The company was founded by Jia Yueting in May 2014 and is headquartered in Gardena, CA.

Faraday Future Intelligent Electric Inc - Ordinary Shares - Class A

Faraday Future Intelligent Electric Inc

Faraday Future is seeing heightened volatility and social media buzz as the company attempts to pivot its narrative toward Embodied AI and robotics partnerships while navigating investor skepticism. Community sentiment remains sharply polarized between bulls betting on a potential turnaround or short squeeze and vocal critics warning of historical dilution, reverse split risks, and long-standing governance concerns.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors show renewed interest in the stock's turnaround potential, driven by recent bullish technical breakouts and anticipation surrounding upcoming earnings. The community is actively debating the company's long-term integration of mortgage and title services, with many traders optimistic that the stock could see significant upside if it sustains momentum above key technical resistance levels.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors digest a strong earnings beat, hiked financial guidance, and a significant share buyback program that has sparked optimism regarding its turnaround strategy. The community is actively debating the stock's potential for further recovery, with many focusing on the balance between long-term institutional trust, the impact of AI-driven cost controls, and the ongoing volatility surrounding healthcare regulatory environments.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant market attention as traders bet on a potential short squeeze, driven by elevated short interest and anticipation surrounding upcoming earnings. The stock's recent volatility and high trading volume have sparked intense community debate, with bulls focusing on enterprise contract growth and long-term agentic AI integration, while skeptics warn of ongoing cash burn and dilution risks.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates its long-term potential in AI data center power efficiency versus skepticism over its current valuation and lack of major design win announcements. Traders are actively analyzing recent institutional activity and management changes while hedging against volatility with significant option activity leading up to upcoming earnings.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is seeing increased investor focus due to its role in the emerging post-quantum cybersecurity sector, bolstered by significant collaborations and a shift toward government-grade, quantum-resistant hardware. While the community is actively debating the company's valuation, cash position, and the impact of dilutive financing, many are highlighting the strategic importance of their hardware-focused approach in an era of rapidly advancing quantum threats.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending on the back of bullish sentiment surrounding significant insider stock acquisitions by leadership and increased momentum from strategic partnerships in the defense and aerospace sectors. Investors are actively discussing the stock's potential for a short squeeze, supported by heavy short interest, while community debates focus on whether recent government contract wins signal long-term business maturation or a fleeting sentiment spike.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is navigating a high-stakes obesity drug market as the launch of Eli Lilly's oral GLP-1 therapy intensifies competition, prompting the company to leverage new data highlighting the efficacy and patient preference of its oral Wegovy. The community remains focused on this ongoing competitive narrative, with many actively debating whether Novo's clinical edge can offset the convenience and scalability of rival treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Amgen Inc. (<a class="mention" data-mention="$AMGN" data-symbol-id="AMGN" href="https://stocktwits.com/symbol/AMGN" target="_blank">$AMGN</a>) edged down 0.3% in premarket trading Wednesday,&nbsp;on course&nbsp;to extend a losing streak to a third consecutive session.&nbsp;The decline follows the <a target="_blank" rel="noopener noreferrer nofollow" href="about:blank">release</a> of Phase 2 study data for its investigational weight-loss drug MariTide, which delivered mixed reactions from Wall Street despite showing some promising results.Amgen reported that MariTide achieved an average weight loss of up to 20% over a year without plateauing, meeting the efficacy bar set by some analysts.&nbsp;However, the results fell short of igniting enthusiasm on Wall Street, with concerns over tolerability and competitive positioning dominating the conversation.RBC Capital analyst Gregory Renza reduced his price target for Amgen to $330 from $360, maintaining an ‘Outperform’ rating.&nbsp;Renza noted that while the drug’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.&nbsp;On the positive side, MariTide’s monthly or less frequent dosing schedule could distinguish it from competitors, but questions around its ultimate profile in the obesity market persist, he added.Truist analysts, meanwhile, compared MariTide’s weight-loss efficacy to Eli Lilly’s (<a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">$LLY</a>) tirzepatide, which boasts up to 21% weight loss, and flagged gastrointestinal issues as a drawback for Amgen’s candidate.&nbsp;They emphasized the drug’s potential to stand out by targeting cardiometabolic benefits but highlighted the fierce competition in the obesity drug landscape.H.C. Wainwright took a more critical stance, suggesting that Viking Therapeutics’ (<a class="mention" data-mention="$VKTX" data-symbol-id="VKTX" href="https://stocktwits.com/symbol/VKTX" target="_blank">$VKTX</a>) VK2735, which uses weekly injections, has demonstrated faster and more effective weight loss. While monthly dosing might benefit MariTide, the firm believes this is not enough to offset the stronger safety and efficacy data from Viking’s offering.Despite the lukewarm response from analysts, retail sentiment for Amgen on Stocktwits turned ‘extremely bullish’ amid a spike in message volume.<figure class="image"><a href="https://stocktwits.com/symbol/AMGN"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AMGN_sentiment_and_message_volume_Nov_27_premarket_74b8d55059.png" alt="AMGN sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>AMGN sentiment and message volume Nov 27 premarket as of 8:15 am ET | source: Stocktwits</figcaption></figure>A Stocktwits poll shows that 73% of retail investors deemed the stock oversold, citing the recent dip as a “great buying opportunity.” Only 15% agreed it was a “fair drop”, based on lingering competitive concerns.Some optimists pointed to JPMorgan saying that MariTide demonstrates clear effectiveness and convenient dosing, although the bar for weight-loss drugs is rising.&nbsp;<stembedurl>https://stocktwits.com/Alexggtrader/message/594230223</stembedurl>Others also cited Piper Sandler’s Christopher Raymond, who has advised investors to wait for longer-term data.<stembedurl>https://stocktwits.com/Wallst45/message/594226329</stembedurl>Amgen shares have lost nearly 6% year-to-date, underperforming broader biotech indices.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bgne-stock-rises-on-eu-approval-for-tevimbra/cJI0HdFRWE">BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows</a>

RBC Capital analyst Gregory Renza reduced his price target for Amgen to $330 from $360, maintaining an ‘Outperform’ rating. 

Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’

An RBC Capital analyst noted that while MariTide’s efficacy aligns with the brokerage’s expectations, its tolerability and long-term dosing regimen leave room for improvement.

XBB.TSX
iShares Core Canadian Universe Bond Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBB.TSX News

XBB.TSXiShares Core Canadian Universe Bond Index ETF